echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO: Entratinib is safe and effective in the treatment of locally advanced or metastatic ROS1 fusion-positive NSCLC, and the intracranial ORR can reach 79.2%

    JCO: Entratinib is safe and effective in the treatment of locally advanced or metastatic ROS1 fusion-positive NSCLC, and the intracranial ORR can reach 79.2%

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Entritinib's overall efficacy (ORR of 67.


    The Journal of Clinical Oncology yesterday released the latest updates of three phase I or phase II clinical trials (ALKA-372-001, STARTRK-1 and STARTRK-2) of Entratinib in ROS1 fusion-positive non-small cell lung cancer ( NSCLC ) Comprehensive analysis results.


    NSCLC

    The gene rearrangement of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) is a carcinogenic driver of non-small cell lung cancer (NSCLC).


    Therefore, researchers have a new idea to extend the follow-up time and confirm in a larger population that Entratinib can be used in patients with locally advanced or metastatic ROS proto-oncogene 1 (ROS1) fusion-positive non-small cell lung cancer (including baseline The effectiveness and safety of patients with central transfer?

    This study included adult patients with locally advanced or metastatic ROS1 fusion-positive NSCLC, with or without CNS metastasis.


    In the population with a follow-up longer than 6 months and comprehensive efficacy evaluation (n = 161), STARTRK-2 was enrolled in 145 cases, STARTRK-1 was enrolled in 7 cases, and ALKA-372-001 was enrolled in 9 cases.


    Through BICR assessment, the target lesions of most patients became smaller, and a clear objective remission was achieved in 108 patients (67.


    The ORR was 67.


    The ORR was 67.


    The intracranial ORR of 24 patients with CNS metastasis was 79.


    According to the investigator's assessment, after BICR scans were performed on the scan results of patients with central nervous system diseases at baseline, 46 patients with central nervous system metastases were confirmed.


    Among the 24 patients with measurable CNS metastases at baseline, the intracranial ORR was 79.


    Among the 24 patients with measurable CNS metastases at baseline, the intracranial ORR was 79.


    The security situation is consistent with the previous report.


    Most AEs are low-grade, manageable , and comparable to other ROS1 inhibitors.


    Entratinib continues to show a high degree of clinical benefit in patients with ROS1 fusion-positive NSCLC, especially in patients with CNS metastases.


    Rafal Dziadziuszko, Matthew G.


    org/doi/abs/10.
    1200/JCO.
    20.
    03025">Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    DOI: 10.
    1200/JCO.
    20.
    03025

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.